Clinical Trial Update: PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]

View source ↗

Summary

A terminated Phase 1/2 trial evaluating PEG-interferon alfa-2b in platinum-resistant ovarian, fallopian tube, and peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• PEG-Interferon alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED